Surgaflex™

The only antimicrobial synthetic polymer matrix designed for use in acute and surgical wounds.

Surgaflex™ is a fully synthetic, ultrathin film matrix composed of polyvinyl alcohol with a surface coating containing ionic and metallic silver. Surgaflex™ absorbs wound fluid and contours to underlying wound bed with a powerful and broad-spectrum antimicrobial benefit without cytotoxicity. The polymeric matrix provides a moist healing environment that is conducive to wound healing.

Surgaflex™ contains antimicrobial silver. Ionic and metallic silver. This addition of ionic and metallic silver provides rapid, effective, and sustained antimicrobial activity.1,2,3,4

bioresorbable_icon.svg - Surgaflex™ – Surgical Wounds

Biocompatible Matrix

Fully synthetic biocompatible polymer matrix provides consistent handling characteristics.2

 

contour_icon.svg - Surgaflex™ – Surgical Wounds

Conforms to Wound Bed

Absorbs wound fluid and conforms to the wound bed serving as a functional and biocompatible matrix.2,4

transparent_icon.svg - Surgaflex™ – Surgical Wounds

Transparent & Synthetic

Allows for clear view of wound bed, isn’t of human or animal origin, and holds a long room-temperature shelf life.1

toxicity_icon.svg - Surgaflex™ – Surgical Wounds

Non-Toxic & 99.99% Effective

99.99% effective against a broad spectrum of wound related microbes.3

Surgaflex™

Clinically Proven

In a Prospective Clinical Case Series published in the October 2021 edition of WOUNDS journal, 22 diabetic patients undergoing various surgical procedures were evaluated. 

Inclusion Criteria: Diabetic patients – a 13% historical SSI rate. The study’s primary objective was to decrease this rate to 6.5% by prophylactic treatment using Surgaflex™

Procedure: Surgical procedures included amputation, removal of exostosis, midfoot bone removal, Achilles’ tendon repair, bunionectomy, or an elevating osteotomy with primary closure of the wound. Patients were assessed on day 3 or 5 for SSI incidence and followed for 90 days.

Results: The per-protocol patient population (20/22) had a 0% SSI rate with healing times typical to the procedure (between 10 and 34 days). Two patients were not included in the analysis due to non-compliance.9